MRK vs ZTS
MRK: Global pharmaceutical and vaccine leader with oncology, infectious disease, and animal health franchises, anchored by blockbuster immunotherapy Keytruda. ZTS: Zoetis is the world's leading animal health company, providing a comprehensive portfolio of medicines, vaccines, and diagnostic technologies for both pets and livestock.
Side-by-side fundamentals
| Metric | MRK | ZTS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $127.47 | $74.19 | |
| Market cap as of 2026-07-23 | $315.3B | $31.7B | |
| P/E as of 2026-07-23 | 35.29 | 12.01 | ZTS lower |
| PEG as of 2026-07-23 | 4.34 | 1.69 | ZTS lower |
| Net margin as of 2026-07-23 | +13.6% | +27.8% | ZTS higher |
| Gross margin as of 2026-07-23 | +78.1% | +71.8% | MRK higher |
| Operating margin as of 2026-07-23 | +18.2% | +34.8% | ZTS higher |
| ROE as of 2026-07-23 | +17.9% | +62.4% | ZTS higher |
| ROA as of 2026-07-23 | +7.0% | +17.5% | ZTS higher |
| Debt / equity as of 2026-07-23 | 1.07 | 2.80 | MRK lower |
| Revenue growth (YoY) as of 2026-07-23 | +2.9% | +2.4% | MRK higher |
| Revenue CAGR (3y) SEC XBRL | +3.1% | +5.4% | ZTS higher |
| Dividend yield as of 2026-07-23 | +2.7% | +1.6% | MRK higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-07-23 | 0.21 | 0.74 | |
| 1-year return as of 2026-07-22 close | +56.2% | -50.9% | MRK higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.